North America Digital Twins in Healthcare Market Report Scope & Overview:

The North America Digital Twins in Healthcare Market was valued at USD 0.94 Billion in 2025 and is projected to reach USD 29.77 Billion by 2035, registering a CAGR of 41.27% from 2026 to 2035.

The North America Digital Twins in Healthcare Market continues to lead global adoption as a dense concentration of leading health systems, academic medical centers and technology vendors pilot early-stage digital-twin applications across imaging, therapy planning and hospital operations. Deep cloud-computing infrastructure and AI research talent concentrated across the United States and Canada continue giving regional health systems an early-mover advantage in building internal digital-twin expertise ahead of health systems in other regions.

Growing venture and strategic investment in precision-medicine and AI-enabled care platforms continues reinforcing North America's position as the largest national-market concentration tracked in this report. Hospital networks are increasingly partnering with cloud-computing providers to deploy patient-specific and operational digital twins at scale, and expanding regulatory clarity from U.S. and Canadian health authorities is gradually easing commercialization pathways for new digital-twin applications across the region.

⮞In 2026, Microsoft expanded its healthcare cloud capabilities through Azure Health Data Services, supporting the integration and analysis of clinical, imaging and device data for healthcare analytics and AI-driven applications.

Global Digital Twins in Healthcare Market Size

The Global Digital Twins in Healthcare Market was valued at USD 2.22 billion in 2025, and the figure is forecast to grow to USD 69.67 billion in 2035, at a CAGR of 41.17% between 2026 and 2035. This growth will be largely driven by growing adoption of AI-based personalized medicine, predictive healthcare modeling, and virtual simulation.

By Type, Process & System Digital Twin Dominates the North America Digital Twins in Healthcare Market, Product Digital Twin Grows Fastest

Process & System Digital Twin solutions dominated North American demand, reflecting hospitals' early focus on operational efficiency gains that deliver measurable cost savings without requiring regulatory clearance for patient-facing clinical use. Large U.S. and Canadian hospital networks continue favoring process-level twins as the natural entry point for building internal digital-twin expertise before expanding into patient-specific clinical applications. Established health-information-technology budgets across the region further reinforce this segment's dominant revenue contribution relative to newer product-level applications still gaining regulatory traction. Growing availability of off-the-shelf operational-twin software is further lowering the barrier to entry for smaller regional hospital systems.

Product Digital Twin services are poised to drive growth as North American medical-device companies become more reliant on digital twins in both medical device development and post-market surveillance. The increased interest by the FDA in using digital twins to validate medical devices further propels this above-average growth rate, particularly with respect to implantable and surgical medical devices, which require expensive physical testing. Greater cooperation between the device manufacturers and simulation software providers hastens the use of product-level digital twins throughout the medical device development process. Increasingly specific patient needs for implants and sizing simulations increase the applicability of the technology.

⮞In October 2025, Johnson & Johnson MedTech advanced product-level digital-twin development by using NVIDIA Isaac for Healthcare to simulate operating-room environments and patient anatomy for its MONARCH™ Platform for Urology, supporting virtual procedure planning, system development and clinical-team training.

By Application, Personalized Medicine Dominates the North America Digital Twins in Healthcare Market, Drug Discovery Grows Fastest

Personalized Medicine applications dominated North American demand as health systems increasingly deploy patient-specific digital twins to model individualized treatment responses across oncology, cardiology and chronic-disease management. Growing clinician confidence in simulation-informed treatment planning, reinforced by outcomes data accumulating at leading U.S. academic medical centers, continues strengthening this application's position as the largest regional revenue contributor. Expanding integration between electronic health records and digital-twin platforms is further embedding personalized-medicine applications into routine clinical workflows. Growing payer interest in outcomes-based reimbursement is additionally reinforcing demand for simulation-informed treatment pathways.

Drug Discovery applications are forecast to grow fastest as North American pharmaceutical developers increasingly use patient-population digital twins to simulate trial outcomes and reduce late-stage clinical failure rates. Growing adoption of virtual control arms and in-silico trial design is reinforcing this above-average growth trajectory across both large originator companies and smaller biotech sponsors concentrated in major U.S. biotech hubs. Expanding collaboration between drug developers and specialized simulation-software vendors is further accelerating demand for drug-discovery-focused capacity. Rising FDA openness to simulation-supported submissions is further reinforcing this application's above-average growth outlook across the pharmaceutical industry.

⮞In May 2026, Twin Health introduced its GLP-1 Stewardship Model, using its AI-powered digital-twin care platform to personalize obesity-treatment management, support sustained weight loss and help employers and health plans manage long-term treatment costs.

By End-use, Hospitals and Clinics Dominate the North America Digital Twins in Healthcare Market, Clinical Research Organizations Grow Fastest

Hospitals and Clinics accounted for the largest end-use share across North America, reflecting their position as both the primary adopters and largest potential beneficiaries of operational and patient-specific digital-twin applications. Established capital budgets for health-information-technology investment across large U.S. and Canadian hospital networks continue reinforcing this segment's dominant revenue contribution. Multi-facility hospital networks are particularly well positioned to justify digital-twin investment given the scale economies available across shared operational and clinical modeling platforms. Growing administrator familiarity with simulation-based planning tools is further reinforcing this segment's entrenched adoption advantage across large hospital networks. Several large hospital systems have further consolidated vendor panels around strategically important technology partners.

Clinical Research Organizations are forecast to grow fastest as North American CROs increasingly offer digital-twin-enabled trial design services to differentiate themselves in a competitive outsourced-research market. Growing sponsor demand for faster, lower-cost trial execution is reinforcing this above-average growth trajectory, particularly for CROs serving smaller biotech companies without in-house simulation expertise. Expanding partnerships between regional CROs and digital-twin technology vendors are further widening the range of trial designs incorporating simulation-based modeling across the outsourced-research industry. Growing numbers of first-time sponsors are further reinforcing this segment's above-average growth outlook across the region.

⮞In March 2026, Unlearn announced that it would support SOLA Biosciences' Phase 1/2 clinical study of SOL-257 for amyotrophic lateral sclerosis using AI-generated digital twins, demonstrating how patient-level simulation can inform early-stage clinical development and treatment-evaluation decisions.

Regional Analysis

US Digital Twins in Healthcare Market Insights

The U.S. dominated the North America Digital Twins in Healthcare Market with the highest revenue share of about 92.52% in 2025, supported by a dense concentration of leading health systems, academic medical centers and technology vendors willing to pilot early-stage digital-twin applications. Microsoft's and GE Healthcare's continued platform-expansion activity continues reinforcing U.S. leadership across nearly every application tracked in this report. Rising venture and strategic investment in precision-medicine platforms has further elevated the strategic priority placed on domestic digital-twin adoption nationwide, with several states competing for new technology-investment projects.

Continued expansion of hospital-system AI investment, growing originator-contractor collaboration between technology vendors and health networks, and sustained federal interest in digital-health modernization reinforce U.S. dominance within North America. Rising investment in cloud-based simulation infrastructure is expected to keep the United States the region's primary revenue engine through the remainder of the decade, with several leading health systems expanding pilot programs into full-scale deployment across multiple clinical and operational use cases and hospital departments.

⮞In January 2025, the U.S. Food and Drug Administration issued draft guidance outlining recommendations for the development, documentation and lifecycle management of AI-enabled medical devices, providing developers with a framework for addressing transparency, bias and safety considerations relevant to emerging simulation-supported healthcare technologies.

Canada Digital Twins in Healthcare Market Insights

Canada is expected to grow at the fastest CAGR of about 42.51% from 2026-2035, facilitated by growing federal research funding for digital-health innovation and rising collaboration between Canadian hospital networks and U.S.-based technology vendors. Growing domestic investment in AI research infrastructure is reinforcing Canada's above-regional growth trajectory as hospital systems across Ontario and Quebec expand digital-twin pilot programs for both operational and clinical applications. Expanding university-affiliated research partnerships are additionally feeding a steady pipeline of new health-technology ventures across Ontario and Quebec.

Continued investment by regional technology vendors in Canadian distribution and technical-support infrastructure, combined with growing interest from academic medical centers, is supporting faster-than-average volume growth across the country through the forecast period. Expanding cross-border collaboration with U.S. health-technology companies is expected to reinforce this pattern through the remainder of the decade as Canadian hospital networks continue aligning digital-twin adoption with U.S. regulatory and technical standards across multiple provinces and health authorities nationwide, including Alberta and British Columbia, which continue scaling their own digital-health pilot programs.

⮞In June 2026, the Government of Canada announced CAD 100 million in new federal investment in the VITAL health data platform, expanding secure access to near-real-time clinical information from hospitals to support medical research, clinical trials and AI innovation across the Canadian healthcare system.

Market Dynamics

Growth Drivers: AI-Enabled Care Models and Precision-Medicine Investment

The North American industry is driven by growing hospital investment in operational efficiency technology, expanding precision-medicine and drug-discovery applications for patient-specific simulation, and rising clinician confidence in AI-assisted decision support across the United States and Canada. As health systems prioritize both cost containment and improved clinical outcomes, demand for digital-twin manufacturing and platform capacity continues rising across the region.

Growing cloud-computing capacity investment, reinforced by Microsoft's and Oracle's continued platform expansion, is reinforcing this driver by giving health systems and biotech companies flexible access to simulation infrastructure. Expanding collaboration between technology vendors and hospital networks is further widening the addressable customer base able to justify early digital-twin platform investment across the region.

⮞In August 2025, Twin Health announced a USD 53 million investment led by Maj Invest to expand its AI-powered digital-twin platform for metabolic health among health plans and large employers, illustrating continued investor interest in personalized, data-driven healthcare models.

Restraints: High Implementation Costs and Data-Integration Complexity

High implementation and integration costs continue restraining faster market-wide expansion across North America, as building accurate digital-twin models requires substantial investment in sensors, data infrastructure and specialized modeling expertise before measurable returns materialize. Many smaller U.S. and Canadian hospitals continue lacking the capital and technical staff needed to deploy digital-twin platforms at meaningful scale. Rising cybersecurity and patient-data-protection requirements are further adding to the total cost of deploying new simulation platforms.

Data-integration complexity across fragmented electronic health record systems also complicates digital-twin deployment decisions for health systems operating multiple legacy platforms across the region. Because validating a new digital-twin application against real-world clinical outcomes can take several years, some hospitals continue favoring narrower, lower-risk operational pilots over broader patient-specific clinical deployment. Limited availability of specialized simulation-modeling talent is further constraining the pace of broader regional adoption.

Opportunities: Drug-Discovery Expansion and Cross-Border Collaboration

Growing pharmaceutical sponsor interest in drug-discovery and clinical-trial simulation applications represents a significant opportunity across North America, as technology vendors able to demonstrate measurable reductions in development timelines and trial costs capture meaningful share. Manufacturers positioned early in domestic simulation-platform expansion stand to benefit as digital-health modernization continues through the forecast period.

Expanding cross-border collaboration between U.S. and Canadian health-technology companies offers a second opportunity for vendors able to serve both markets from a single regulatory-compliant platform. Continued collaboration between hospital networks and domestic technology vendors is expected to further accelerate this opportunity through the remainder of the forecast period.

⮞In April 2025, Unlearn and remynd announced a collaboration to analyze an Alzheimer's disease study using AI-generated digital twins, aiming to strengthen confidence in early clinical signals and support interpretation of biomarker trends during the development of potential treatments.

North America Digital Twins in Healthcare Companies are:

• Microsoft Corporation

• IBM Corporation

• Oracle Corporation

• NVIDIA Corporation

• Hewlett Packard Enterprise Company

• GE Healthcare Technologies Inc.

• ANSYS, Inc.

• Altair Engineering Inc.

• Unlearn.AI, Inc.

• Twin Health, Inc.

• Q Bio, Inc.

• Dassault Systèmes SE

• Siemens Healthineers AG

• Philips Healthcare

• Atos SE

• Virtonomy GmbH

• PrediSurge

• InSilicoTrials Technologies, Inc.

• Faststream Technologies

• Cortex Labs

North America Digital Twins in Healthcare Market Report Scope: